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Volume 51, Number 2 Abstracts 523between procedural and clinical success in the treatment of renal artery stenosis
may, at least in part, stem from the limitations of angiography and the assess-
ment of the significance of renal artery stenosis. The authors therefore sought to
compare the diagnostic accuracy of renal artery translesional pressure gradients,
intravascular ultrasound (IVUS) imaging, and angiographic parameters in pre-
dicting hypertension improvement after stenting of renal artery stenosis. Their
hope was to establish criteria where stenting of the renal artery can be justified by
improved hypertension control.
Sixty-two patients with renal artery stenosis had assessment of trans-
stenosis pressure gradients (resting and hyperemic systolic gradient, frac-
tional flow reserve, and mean gradients) as measured by pressure guidewires
and IVUS and angiographic parameters of minimal lumen diameter such as
area stenosis and diameter stenosis. Patients with renal artery stenosis were
enrolled in the study if the systolic blood pressure was140 mm Hg or the
diastolic blood pressure was 90 mm Hg, or both, or they had accelerated
or refractory hypertension on two or three antihypertensive medications.
Hypertension improvement was defined as a diastolic blood pressure of90
mm Hg or a systolic blood pressure of140 mm Hg, or both, or a reduction
in diastolic blood pressure by at least 15 mm Hg with the same or reduced
number of antihypertensive medications. Receiver-operating characteristic
(ROC) analysis determined optimal cutoff values of transpressure gradients,
IVUS parameters, and angiographic parameters in predicting hypertension
improvement at 12 months. Cut points that yield the greatest sum of
sensitivity and specificity were selected. The area under the curve for the
ROC (AUROC) analysis was compared for each of the hemodynamic and
anatomic parameters assessed.
Hyperemic pressure gradients were determined across the renal artery
stenosis by first advancing the pressure wire through the stenosis and then
injecting a 30-mg bolus of papaverine into the renal artery. After the
papaverine injection, the guiding catheter was retracted from the ostial of the
renal artery and the renal artery pressure gradients were obtained.
The hyperemic systolic pressure gradient had a larger AUROC curve
than most other parameters. A hyperemic systolic pressure gradient21 mm
Hg had the highest sensitivity, specificity, and accuracy (82%, 84%, and 84%)
in predicting hypertension improvement after stenting of renal artery steno-
sis. Stenosis as determined by the average IVUS area was significantly greater
in renal artery lesions with a hyperemic systolic pressure gradient 21 mm
Hg vs those with gradients 21 mm Hg (78% vs 38%, P  .001). In 36
patients with hyperemic systolic pressure gradients 21 mm Hg, hyperten-
sion improved in 84% after renal artery stenting. In patients with hyperemic
systolic gradients21 mm Hg, hypertension improved in 12 months in 36%
of patients (n  26, P  .01). Multivariable analysis showed the hyperemic
systolic pressure gradient was the only parameter that independently pre-
dicted hypertension improvement (odds ratio, 1.39; 95% confidence inter-
val, 1.05-1.65; P  .013).
Comment: The problem with this study, of course, is that hyperemic
systolic pressure gradients can only be obtained once a catheter is placed
across the renal artery lesion. The practical point is that once someone has
placed a wire across the renal artery lesion, it would be very difficult to avoid
the temptation to stent that lesion regardless of the pressure gradient
measured. The concept that hemodynamic gradients are more important
than the angiographic severity is likely valid and makes sense. A correlation
with hyperemic systolic pressure gradients with ultrasound findings would
seem to be the next step in trying to determine the practicality of hyperemic
pressure gradients in selecting patients for renal artery stenting. See also the
abstract “Revascularization vs. medical therapy for renal-artery stenosis” by
the ASTRAL investigators in this abstract section of the journal.
Racial and Ethnic Disparities in Outcomes and Appropriateness of
Carotid Endarterectomy: Impact of Patient and Provider Factors
Halm EA, Tuhrim S, Wang JJ, et al. Stroke 2009;40:2493-501.
Conclusion: Minorities have worse outcomes and higher rates of
inappropriate carotid endarterectomy (CEA).
Summary: There are many variables that lead to inequities in quality
and outcomes of health care. Access to care, particularly adequate insurance,
appears to be a major driver of disparities in care. However, inequities exist
even among well-insured patients. Other possible drivers of inequities in
health care include racial and ethnic differences and underlying social
demographic characteristics, as well as severity of comorbid illnesses and
overall disease burden. Minority patients may also receive care by physicians
and in hospitals with lower levels of cultural competence than would be
ideal. There is therefore a current emphasis on identifying how patients’
disease burden and physician or hospital factors, or both, can contribute to
disparities among care in minority patients.
This study evaluated disparities and outcomes of CEA with respect to
race and ethnicity. This was a population-based cohort of CEA patients
derived from a list of Medicare beneficiaries in New York. Data were
abstracted from medical records to assess social demographics, disease
severity, comorbidities, indication for CEA, and strokes and deaths within
10 days of surgery. Appropriateness of CEA was based on validating criteria
from a national expert panel. Differences in providers, patients, appropriate-
ness of surgery, and outcomes were compared using 2 tests. Multiplelogistic regression analysis was used to evaluate differences in risk-adjusted
rates of death or nonfatal stroke with adjustments for patient, physician, and
hospital-level risk factors.
Of 9093 patients undergoing CEA overall, 95.3% were white, 2.5%
were black, and 2.2% were Hispanic. Analysis indicated minorities had more
severe neurologic disease, more comorbidity, and were more likely to be
cared for by lower-volume surgeons and hospitals (P  .0001). The 30-day
stroke and death rates were higher in Hispanics (9.5%) and blacks (6.9%)
than in whites (3.8%, P .0001). When adjusting for presurgical patient risk
and provider characteristics, multivariable analysis indicated that blacks no
longer had significantly worse outcomes (odds ratio, 1.37; 95% confidence
interval, 0.78-2.40). Even after adjustments, however, a higher risk of death
and stroke persisted in Hispanic patients (odds ratio, 1.87; 95% confidence
interval, 1.07-3.19). This was largely due to higher comorbidity in minori-
ties and higher rates of inappropriate surgery (Hispanics, 17.6%; blacks,
13.0%; whites, 7.9%; P  .0001).
Comment: This study suggests that, at least with regard to endarter-
ectomy, surgical outcomes in minority patients are driven largely by patient
presurgical risk and experience and skill of the specific physicians performing
the procedure. That Hispanic patients have the highest incidence of periop-
erative stroke after CEA is a new finding. Adjustment for patient, surgeon,
and hospital factors diminished excess risk among Hispanics, but Hispanic
patients still had nearly double the risk of death or stroke in the multivariable
model used. The interaction of Hispanic people with the medical system has
received relatively little attention. Thankfully, this now appears to be chang-
ing.
Revascularization vs Medical Therapy for Renal-Artery Stenosis
The ASTRAL Investigators. N Engl J Med 2009;361:1953-62.
Conclusion: There is no significant clinical benefit from renal artery
revascularization in patients with renal artery atherosclerotic disease.
Summary: Renal artery stenosis is associated with chronic kidney
disease and hypertension. It is, however, not clear that these associations are
causal. In fact, three small randomized control trials have showed no benefit
of renal artery angioplasty compared with medical therapy (Hypertension
1998;31:823-9; J Hum Hypertens 1998;12:329-35; N Engl J Med 2000;
342:1007-14). These studies were small and underpowered to detect po-
tentially clinically worthwhile improvements in renal function, blood pres-
sure, or mortality rates. The current Angioplasty and Stent for Renal Artery
Lesions (ASTRAL) trial is a randomized unblinded trial in which 806
patients with atherosclerotic renal vascular disease were assigned to undergo
medical therapy alone or renal revascularization (renal angioplasty with or
without a stent and without renal protection) in addition to medical therapy.
Renal function measured by the reciprocal of the serum creatinine level (a value
that has a linear relationship with creatinine clearance) was the primary outcome
measure. Secondary outcomes were the times to renal and major cardiovascular
events, death, and blood pressure. Medium follow-up was 34 months.
During a 5-year period, progression of renal impairment (defined by
the slope of the reciprocal of the serum creatinine level) was –0.07  10–3
L/mol per year in the revascularization group and –0.13 10–3 L/mol
per year in the medical therapy group. This difference of 0.06  10–3
L/mol per year favors revascularization (95% confidence interval [CI],
–0.002 to 0.13; P .06). Mean serum creatinine was 0.02 mg/dL lower in
the revascularization group than in the medical therapy group (95% CI,
–0.10 to 0.06). There was no significant difference between groups in
systolic blood pressure. The decrease in diastolic blood pressure was smaller
in the revascularization group than in the medical therapy group. There were
similar rates of renal events in the two groups (hazard ratio in the revascu-
larization group: 0.97; 95% CI, 0.67-1.4; P  .88). There were no signifi-
cant differences in major cardiovascular events (P .61) and death (P .46)
between the two groups. In the revascularization group, 23% of patients had
significant complications associated with revascularization, including three
amputations of toes or limbs and two deaths.
Comment: The study indicates no benefit from revascularization in
patients with renal artery stenosis. The authors also performed post hoc
analyses in smaller subpopulations of patients. They found no evidence of
benefit of revascularization in patients with bilateral renal artery stenosis
70% or renal artery stenosis 70% in a single functioning kidney. There
was also no significant difference in outcome between patients with severe
renal artery stenosis vs those without severe disease. Renal artery revascular-
ization for atherosclerotic disease should now be a rare event. Treatment of
renal artery stenosis simply because “it can’t be a good thing” cannot be
justified.
Secondary Intervention After Endovascular Abdominal Aortic Aneu-
rysm Repair
Conrad MF, Adams AB, Guest JM, et al. Ann Surg 2009;250:383-9.
Conclusion: Secondary interventions are common after endovascular
aneurysm repair but do not adversely affect aneurysm related death or overall
actuarial 5-year survival.
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formed in patients who have undergone endovascular aneurysm repair
(EVAR). Rates of secondary intervention range from 10% to 18%, with most
problems addressed with endovascular procedures. The authors sought to
determine the indications for secondary interventions after EVAR in their
institution and the effect of these interventions on long-term survival.
From January 1997 to December 2007, 832 patients underwent
EVAR. All grafts placed in this study were Food and Drug Administration
approved and included the Cook Zenith graft, Gore Excluder, Medtronic
AneuRx graft, and the Endologix Powerlink graft. Grafts were placed by
vascular surgeons in the operating room using fixed imaging assistance. (The
article did not specify who performed catheter-based secondary interven-
tions.) Patients undergoing secondary interventions were stratified accord-
ing to indications and the specific nature of the secondary intervention and
treatment. Study end points were aneurysm-related and overall survival, and
freedom from secondary intervention. At a mean follow-up of 35 months,
91 patients (11%) underwent 131 secondary interventions. There were no
demographic features that predicted the need for a secondary intervention.
The 5-year survival from secondary interventions was 80%, and 76% of the
secondary interventions were accomplished with a catheter-based approach.
Secondary interventions were successful80% of the time for all indications
except type II endoleak, where the initial secondary intervention was suc-
cessful only 34% of the time. Multivariate analysis predicting secondary
interventions identified aneurysm sac size 5.5 cm (odds ratio, 2.1; P 
.004) and preprocedure coil embolization of hypogastric or inferior mesen-
teric artery (odds ratio, 2.1; P  .008) as predictors of secondary interven-
tions. The 5-year actuarial survival was 70% and aneurysm-related survival
was 97.5%. There was no survival difference in patients who underwent
secondary interventions compared with those who did not.
Comment: This is a large series of EVARs from an institution known
for excellence in treatment of aneurysm disease. The authors report a rate of
secondary interventions is in the low range of those previously reported.
There is no obvious explanation for this in the data presented. Clearly,
secondary interventions after EVAR are at the discretion of the attending
surgeon, and some centers will have a more conservative approach than
others. It is interesting to note that an aneurysm 5.5 cm was associated
with an increased need for secondary interventions. A cynic might point out
that secondary interventions are more common when EVAR was actually
indicated in the first place!
The article would have been strengthened by more details regarding
patient follow-up. We do not know how many of the patients in this series
were followed per protocol, how many computed tomography scans were
performed per patient, or how many patients were lost to follow-up. It
perhaps would have been preferable to report the rate of intervention as a
function of patient-years of follow-up. Overall, the data again suggest thesafety of EVAR and its effectiveness in preventing aneurysm-related death.
Rates of secondary intervention seem reasonable from what we have come to
expect. The rate of secondary interventions in any series will depend on the
completeness of follow-up of the patients, per protocol follow-up of pa-
tients, the number of patient-years of follow-up, and individual surgeon
threshold for performing secondary interventions.
Strokes After Cardiac Surgery and Relationship to Carotid Stenosis
Li Y, Walicki D, Mathiesen C, et al. Arch Neurol 2009;66:1091-6.
Conclusion:There is no causal relationship between significant carotid
stenosis and stroke after cardiac surgery.
Summary: There are potentially multiple mechanisms for stoke after a
cardiac surgical procedure, including carotid artery stenosis, cardiac arrhythmia,
aortic atherosclerosis, transient hypercoagulable states, and hypertension. These
multiple and often coexisting causes make studying the mechanism of stroke
after cardiac surgery difficult. Estimates are that in 2001, 5000 combined
cardiac and carotid operations were performed in the United States (Neurology
2007;63:195-97). Recent analyses suggest increased stroke and death after
combined procedures (Neurology 2007;68:195-7; Neurology 2005;64:1435-7).
In this study of 4335 patients undergoing coronary artery bypass grafting or
aortic valve replacement, or both, the authors sought to define the incidence
and arterial distribution of stroke after the procedure.
Clinically definite stroke on the same hospital admission was detected
in 1.8% of patients. Only 5.3% of these strokes were of large vessel type, and
76.3% occurred in patients without significant carotid stenosis. In 60% of
patients, strokes visible on computed tomography scanning were not con-
fined to a single carotid artery distribution, and 95% occurred without direct
correlation to a significant carotid stenosis. Patients who underwent com-
bined carotid and cardiac operations had an increased risk of postoperative
stroke than did patients with similar degrees of carotid stenosis but who did
not undergo a combined procedure (15.1% vs 0%; P  .004).
Comment: A randomized trial exploring the efficacy of combined
cardiac and carotid surgery is never going to happen. Such a trial would
require too many patients and have a prohibitively high cost. Case series such
as this, although not ideal, are therefore going to remain the only source of
information upon which practitioners can base the decision about whether
to perform cardiac and carotid procedures at the same setting. The data
suggest that such a tactic is actually harmful to patients. The authors point
that if one assumes 5000 combined carotid endarterectomies and cardiac
operations are performed annually in the United States, avoidance of these
combined procedures could prevent nearly 500 postoperative strokes each
year after cardiac surgery!
